Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants.

ABSTRACT:

Importance

Respiratory syncytial virus (RSV) is the leading cause of infant hospitalizations, and preterm infants and those with older siblings are at increased risk. Despite recommendations for nirsevimab prophylaxis, data on outcomes in high-risk infants are lacking.

Objective

To assess the association of nirsevimab prophylaxis with RSV-related lower respiratory tract infection (LRTI) hospitalization risk and in-hospital severity among infants, overall and by high-risk groups.

Design, setting, and participants

This retrospective multicenter cohort study comparing RSV seasons before (April 1, 2023, to March 31, 2024) and after (April 1, 2024, to March 31, 2025) universal nirsevimab prophylaxis implementation included all live births from 5 neonatal hospitals serving

SUBMITTER: Cocchi E 

PROVIDER: S-EPMC12635873 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature